Oral Combination Therapy for T2D

Slides:



Advertisements
Similar presentations
What's New in Basal Insulin for Diabetes
Advertisements

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
New Data on the Safety of SGLT2 Inhibitors
An Update on Oral Prostanoids: Advancing Care for PAH?
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
Goals of Therapy for Patients With UC
SGLT2 Inhibitors and Their Clinical Impact:
Global Projections for Diabetes:
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Ask the Onychomycosis Expert, Part 2
What Comes Second?.
Insulin/GLP-1 Agonist Combinations
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
SGLT2 Inhibitors in Phase 3 Trials
Updates Abound.
SGLT2 Inhibitors in the Modern Era: Why and Where?
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Emerging CVOT Data and Clinical Application
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.
GLP-1 Receptor Agonists: How Early Is Appropriate?
T2DM and CV Outcomes Trials: A Deep Dive!
A Deep Dive Into CVOTs.
ADA/EASD Position Statement: Approach to Hyperglycemia Management
UKPDS 34: Metformin vs Conventional Glycemic Control on Outcomes
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Tackling CV Risk in T2DM.
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Early and Intensive T2D Management:
Breaking Down the CVOTs
Insulin/GLP-1 Agonist Combinations
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
LEADER One Year On.
Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
Antihyperglycemic Therapy
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
Modern Advances in Glucose Monitoring
T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
The Role of the Kidney in Glucose Control
Dual SGLT1/SGLT2 Inhibition in T1D
The Changing Field of Melanoma: Ipilimumab.
Add-On Therapy to Insulin in T1DM Management
Patient Selection for Modern T2D Agents
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Improving Overall Health
2015 EASD In Review: CV Risk management in t2dm
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Statin Selection in Patients With Pre-Diabetes: Case Considerations
New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future
Fixed-Ratio Combination Therapy in T2DM
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Antihyperglycemic therapy in adults with type 2 diabetes
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
In the Know.
Presentation transcript:

Oral Combination Therapy for T2D

SGLT2i Newest Antihyperglycemic Class

DPP-4i Mechanism of Action

Glycemic Control Algorithm and Goals

Combination Therapy SGLT2i Plus DPP-4i

Change in HbA1c With Combination Empa and Lina Therapy

Why Are Effects of FDCs Not Additive?

Percentage of Patients Achieving HbA1c of Less Than 7% With Combination Empa and Lina Therapy

Considerations for Combination Therapies in Clinical Practice

Percentage of Patients Achieving HbA1c of Less Than 7% With Combination Dapa Plus Saxa Therapy With Metformin

Common Side Effects of FDC Components

Uptake of FDCs

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.